BACKGROUND & AIMS: Mesalamine is a mainstay therapeutic agent in chronic ulcerative colitis (CUC) in which condition it reverses crypt architectural changes and reduces colitis-associated cancer (CAC). The present study addressed the possibility that mesalamine reduces beta-catenin-associated progenitor cell activation, Akt-phosphorylated beta-catenin(Ser552) (P-beta-catenin), and colitis-induced dysplasia (CID). METHODS: Effects of mesalamine on P-beta-catenin staining and function were assessed by immunohistochemistry and quantitative reverse-transcription polymerase chain reaction (qRT-PCR) in biopsy specimens of CUC in mild or "refractory" severe mucosal inflammation. Effects of mesalamine on epithelial proliferation and activation of Akt and beta-catenin were assessed in interleukin (IL)-10(-/-) colitis and CID by immunohistochemistry and Western blotting. Dysplasia was assessed by counting the number and lengths of lesions per colon. RESULTS: Data from IL-10(-/-) and human colitis samples show that mesalamine reduced Akt activation and P-beta-catenin levels in the middle and upper crypt. Reductions in P-beta-catenin in CUC biopsy specimens with severe inflammation suggested that mesalamine reduced P-beta-catenin levels in tissue refractory to mesalamine's anti-inflammatory effects. In IL-10(-/-) mice, mesalamine reduced CID concordant with inhibition of crypt Akt and beta-catenin signaling. CONCLUSIONS: The results are consistent with the model that mesalamine contributes to chemoprevention in CAC by reducing beta-catenin signaling within intestinal progenitors.
BACKGROUND & AIMS:Mesalamine is a mainstay therapeutic agent in chronic ulcerative colitis (CUC) in which condition it reverses crypt architectural changes and reduces colitis-associated cancer (CAC). The present study addressed the possibility that mesalamine reduces beta-catenin-associated progenitor cell activation, Akt-phosphorylated beta-catenin(Ser552) (P-beta-catenin), and colitis-induced dysplasia (CID). METHODS: Effects of mesalamine on P-beta-catenin staining and function were assessed by immunohistochemistry and quantitative reverse-transcription polymerase chain reaction (qRT-PCR) in biopsy specimens of CUC in mild or "refractory" severe mucosal inflammation. Effects of mesalamine on epithelial proliferation and activation of Akt and beta-catenin were assessed in interleukin (IL)-10(-/-) colitis and CID by immunohistochemistry and Western blotting. Dysplasia wasassessed by counting the number and lengths of lesions per colon. RESULTS: Data from IL-10(-/-) and humancolitis samples show that mesalamine reduced Akt activation and P-beta-catenin levels in the middle and upper crypt. Reductions in P-beta-catenin in CUC biopsy specimens with severe inflammation suggested that mesalamine reduced P-beta-catenin levels in tissue refractory to mesalamine's anti-inflammatory effects. In IL-10(-/-) mice, mesalamine reduced CID concordant with inhibition of crypt Akt and beta-catenin signaling. CONCLUSIONS: The results are consistent with the model that mesalamine contributes to chemoprevention in CAC by reducing beta-catenin signaling within intestinal progenitors.
Authors: Daniel J Berg; Juan Zhang; Joel V Weinstock; Hanan F Ismail; Keith A Earle; Hector Alila; Rifat Pamukcu; Steven Moore; Richard G Lynch Journal: Gastroenterology Date: 2002-11 Impact factor: 22.682
Authors: K Krishnan; S Komanduri; J Cluley; R Dirisina; P Sinh; Jeff Z Ko; L Li; R B Katzman; T A Barrett Journal: Dig Dis Sci Date: 2011-09-24 Impact factor: 3.199
Authors: Goo Lee; Tatiana Goretsky; Elizabeth Managlia; Ramanarao Dirisina; Ajay Pal Singh; Jeffrey B Brown; Randal May; Guang-Yu Yang; Josette William Ragheb; B Mark Evers; Christopher R Weber; Jerrold R Turner; Xi C He; Rebecca B Katzman; Linheng Li; Terrence A Barrett Journal: Gastroenterology Date: 2010-05-24 Impact factor: 22.682
Authors: Li-Shu Wang; Chieh-Ti Kuo; Tim H-M Huang; Martha Yearsley; Kiyoko Oshima; Gary D Stoner; Jianhua Yu; John F Lechner; Yi-Wen Huang Journal: Cancer Prev Res (Phila) Date: 2013-10-15
Authors: Mohammad W Khan; Ali Keshavarzian; Elias Gounaris; Joshua E Melson; Eric C Cheon; Nichole R Blatner; Zongmin E Chen; Fu-Nien Tsai; Goo Lee; Hyunji Ryu; Terrence A Barrett; David J Bentrem; Philipp Beckhove; Khashayarsha Khazaie Journal: Clin Cancer Res Date: 2013-03-13 Impact factor: 12.531